Previous 10 | Next 10 |
home / stock / sny / sny articles
First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Nic...
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson&n...
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development program of tusamitamab ravtansine. The decision is ba...
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium announce that the European Medicines Agency’s (EMA) Committee for ...
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic...
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, ...
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbuster potential (to make over $1 billion in annual sales), ...
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agon...
Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobruti...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...
2024-06-09 09:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...